Financebotresearch desk研究台

XYL › analyze

XYL · Analyze

ACCUMULATE Industrials

Price at analysis: $112.65 | 52-week range: $105.29 - $154.27 (-27% off high, +7% off low) | Mkt cap: $26.3B

0. Knowledge Check

python .mcp/kb.py find XYL returned no matches — no live note or prior report on this name. This is a fresh first look; nothing to cite, nothing to contradict.

Relevant Playbook pitfalls checked before trusting vendor numbers (XYL is a plain US domestic filer, not an ADR, so the ADR-specific traps — pitfall-adr-ticker-resolution, pitfall-adr-book-value-corrupts-price-to-book, pitfall-currency-mixed-ev-is-invertible-on-adrs — don't apply here):

  • pitfall-vendor-forward-eps-is-the-wrong-fiscal-year — fired. Yahoo's forwardEps ($6.25, implying an 18.0x forward P/E) does not match Xylem's own FY2026 guidance midpoint ($5.625 adjusted EPS, guided Jul-24-2026). The vendor forward figure is almost certainly blending in FY2027 consensus. Valuation below uses the company's own FY2026 guide, not Yahoo's forward field.
  • pitfall-dyt-inverts-when-price-caused-the-yield — fired. Current yield (1.52%) sits above its 5yr average (1.16%), but the dividend itself has only grown modestly (from ~$1.66 to $1.72 trailing) while the price fell 27% from its high. The elevated yield is price-driven, not dividend-driven — treated as a caution below, not a buy signal.
  • pitfall-divested-segment-corrupts-multiyear-cagr (analogous, inverse direction) — the 3yr revenue/FCF/net-income CAGRs fin.py prints are inflated by the May-2023 Evoqua acquisition (a step change in the denominator, not organic growth). Recomputed on a per-share, deal-adjusted basis below.
  • principle-primary-source-beats-vendor and pitfall-forward-pe-above-trailing-pe-flags-an-inflated-base — checked; forward P/E (18.0x) sits below trailing P/E (27.0x) as expected for a growing earner, so no inversion flag there.

No note exists yet on the GAAP/non-GAAP operating-margin gap found below (fin.py's 17.0% operating margin vs. roic.ai's GAAP 14.7%) — flagged for the orchestrator to consider as a new pitfall candidate; not written here per scope lock.

1. Fundamentals

Cross-validation note

fin.py's snapshot operating margin (17.0%, TTM, likely a Yahoo-adjusted figure) diverges meaningfully from roic.ai's GAAP FY2025 operating margin (14.68%, up from 12.51% FY2024). Gross margin agrees closely (39.2% fin.py vs 38.5% roic.ai FY2025). All margin/ROIC figures below use roic.ai's GAAP annual series as the more conservative, cross-validated basis; the gap itself (roughly 2.3 points) is consistent with amortization of Evoqua-related acquired intangibles sitting inside GAAP opex but excluded from the adjusted figure Xylem itself guides to. This is a real quality-of-earnings wrinkle: the company's adjusted EPS guide ($5.55-5.70 FY26) sits well above its GAAP trailing EPS ($4.17 TTM / $3.92 FY2025) — a ~35-45% gap that is unusually wide for a company this size and is a direct byproduct of still-amortizing the 2023 Evoqua deal.

Free cash flow & the Evoqua distortion

FY Revenue FCF Shares (dil) Rev/sh FCF/sh
2022 $5.52B $388M 181.0M $30.50 $2.14
2023 $7.36B $566M 218.2M $33.73 $2.59
2024 $8.56B $942M 243.5M $35.16 $3.87
2025 $9.04B $910M 244.0M $37.05 $3.73

fin.py's headline "Revenue 17.8% (3y CAGR), FCF 32.9% (3y CAGR)" is not organic — Xylem closed the Evoqua Water Technologies acquisition in May 2023, which added ~$1.6B revenue, roughly doubled the balance sheet (assets $7.95B→$16.11B in one year, goodwill $2.72B→$7.59B), and diluted shares outstanding by ~35% (181M→244M) in a single step. Recomputed per share — the only basis that matters to an owner — the picture is more modest but still genuinely good: FCF/share compounded ~20%/yr 2022-2025, revenue/share only ~6.8%/yr (most of the reported "growth" was the deal, not organic demand). The concerning data point: FCF/share actually fell 3.6% in FY2025 (2024→2025) — the first down year since the deal closed, and it lines up with the guidance narrowing (see Sentiment) rather than being a one-off.

Capital allocation (FY2025, $910M FCF)

Use Amount % of FCF
Dividends $391M 43%
Bolt-on M&A $163M 18%
Net debt paydown $81M 9%
Buybacks $15M 2%

Buybacks are token-sized — essentially offsetting equity-comp dilution rather than a real repurchase program (diluted share count still crept up 0.2% in FY2025). This is a mature-industrial capital-allocation profile: dividend first, disciplined bolt-on tuck-ins second, opportunistic deleveraging third. Nothing aggressive, nothing alarming — no buybacks-at-rich-prices, no empire-building M&A since Evoqua.

Balance sheet — genuinely strong

  • Debt/Assets: 11.7% (roic.ai confirms fin.py exactly)
  • Net Debt/EBITDA: 0.26x (down from 0.57x in FY2024) — essentially unlevered
  • EBITDA/Interest: 62x coverage — no credit risk of any kind
  • Current ratio 1.61x, quick ratio 1.16x — ample liquidity

This is the fundamentals scorecard's clearest strength: a pristine, low-leverage balance sheet with room to both weather a demand air-pocket and keep funding bolt-on deals without stress.

Dividend Grower overlay

  • 15 consecutive years of dividend increases (2011→2026), current $0.43/qtr ($1.72 annualized)
  • Div CAGR: ~9.0%/yr (2021-2026), ~9.4%/yr (2018-2026) — consistent, moderate, no cuts, no freezes even through 2022's margin compression
  • Payout ratio: 40-42% of GAAP EPS (roic.ai: 41.5% FY25), 43% of FCF — well covered on either denominator, with headroom to keep compounding the dividend even if earnings growth slows further

Top/bottom-line growth

Reported growth has decelerated sharply: revenue grew 33.6% (2022→2023, deal-inflated), 16.3% (2023→2024), 5.6% (2024→2025), and guidance now points to ~2% reported / 2-3% organic for FY2026 — a materially slower cadence than the post-deal comp years, and the proximate cause of the de-rating (see Sentiment).

2. Moat & Competitive Advantage

ROIC trend: 6.4% (FY2024) → 7.3% (FY2025) (roic.ai return_on_inv_capital) — improving but still modest for a name trading at 27x trailing earnings. This is not a high-ROIC compounder in the software/consumer-brand sense; it's an industrial-equipment-and-services business earning solid-but-unspectacular returns on a goodwill-heavy asset base (goodwill is 47% of total assets post-Evoqua).

Gross margin trend: 37.5% (FY2024) → 38.5% (FY2025), rising — consistent with a business successfully passing through price and mixing toward higher-margin services/software (Xylem Vue analytics, smart metering) rather than losing pricing power.

Adversarial stress-test — "how would a rival attack?" A well-funded rival cannot easily replicate Xylem's installed base of municipal water/wastewater pumping and treatment equipment (Flygt, Bell & Gossett, Sensus) — these are long-cycle assets (decades of service life) with real switching costs: recertification, spare-parts compatibility, and utility procurement processes that favor incumbents. But the attack surface is real and specific: smart/digital metering (AMI) is a younger, more commoditized, more software-defined layer where Xylem competes against Badger Meter, Itron, and others on cellular connectivity and analytics rather than on installed-base lock-in — and this is exactly the segment (Measurement & Control Solutions) cited for the guidance narrowing this quarter (electric metering project delays). The core water-infrastructure franchise looks durable; the newer digital/metering layer looks contestable.

Disruption vectors: 1. AMI commoditization — the segment most exposed to price competition and project-timing risk (confirmed this quarter). 2. Municipal budget cycles — public-sector customers mean capex is lumpy and politically/rate-case-driven, not demand-driven; delays read as timing risk more than share loss, but they hit reported growth in the same way either way. 3. Integration risk on a goodwill-heavy balance sheet — Evoqua was the largest deal in company history; a soft patch in end markets could eventually force a goodwill-impairment conversation given how much of the asset base it represents.

Evergreen assessment: High. Water and wastewater treatment, municipal infrastructure replacement, and PFAS/emerging-contaminant regulation are structural, multi-decade tailwinds largely independent of the economic cycle — this is about as close to a "forever" end-market as industrials get. The moat is real but moderate, not exceptional: durable core, contestable edges.

3. Valuation

Applied conditionally per the framework — XYL is a moderate-growth dividend grower with real book value, so Graham, Bogle, and DYT/DDM all apply, weighted toward the multiple-based read given the GAAP/adjusted EPS gap noted above.

Model Inputs / assumptions Output
Graham IV √(22.5 × EPS(ttm) $4.17 × BVPS $47.13) $66.50 — well below spot. Graham's formula assumes no growth premium and penalizes the current GAAP/adjusted gap; weight it as a value floor, not a target.
Bogle Expected Return Div yield 1.52% + sustainable growth rate 5.06% (roic.ai: ROE 8.65% × (1−41.5% payout)), ± P/E change ~6.6%/yr with no re-rating, up to ~13-14%/yr if forward P/E mean-reverts from today's 18x back toward its 2024-25 band (mid-20s) over 2-3 years. Wide range — states the multiple-reversion assumption explicitly because it drives most of the upside case.
DYT Current yield 1.52% vs. 5yr avg 1.16% (yield 31% above its own average) Directionally supportive of "cheap vs. own history," but flagged: the dividend has grown only modestly while price fell 27% off its high, so this is a price-driven yield spike, not a dividend-driven one — a caution, not confirmation.
DDM Gordon growth, D0=$1.72, r≈9.25% (10yr ~4.2% + beta 1.01 × 5% ERP) g=6%: ~$56; g=7%: ~$82. Extremely sensitive to the r−g spread at these inputs; treat as a sanity check that the current $1.72 dividend alone, at a conservative long-run growth rate, does not on its own justify $112 — most of the equity value has to come from earnings growth and buybacks, not the dividend stream.

Multiple-based cross-check (primary method here): Using Xylem's own FY2026 adjusted-EPS guidance midpoint ($5.625, not Yahoo's fiscal-year-mismatched $6.25 forward figure) against a 19-23x forward multiple — below the mid-20s band the stock traded in through 2024-2025, appropriate for a business with decelerating organic growth and a modest ROIC — implies a fair-value range of roughly $107-$130. Current price ($112.65) sits almost exactly at a 20x multiple on that guide, i.e. near the low end of the range.

Assumptions stated plainly: the case for "cheap" rests on (a) the sell-off being sentiment/transition-driven rather than a re-rating of the moat (see Sentiment), and (b) the FY2026 guide holding. If the MCS delays prove to be the start of a genuine share-loss story rather than order timing, the multiple deserves to stay compressed and Graham's $66 becomes the more relevant anchor.

Fair value: $107-130. Entry zone: $100-115 (current price is inside it). Trim: 25x fwd (a forward-multiple trim, not a fixed dollar — at the FY2026 guide midpoint that's ~$141 today, and rises as the guide is updated).

4. Sentiment — why is it near its 52-week low right now?

The timeline separates two distinct things that are easy to conflate:

  1. The Q2 FY2026 print itself (reported ~Jul 24, 2026) was received positively. Adjusted EPS of $1.46 beat consensus ($1.34) by ~9%; the company raised full-year adjusted EPS guidance to $5.55-5.70 (from $5.35-5.60) on margin gains (adjusted EBITDA margin guide raised 90-130bp to 23.1-23.5%). The stock rose 2.9-6.8% on the print. The one soft spot: full-year revenue guidance was trimmed to ~$9.2B (from $9.1-9.4B) and organic growth narrowed to 2-3% (from 2-4%), attributed specifically to electric metering project delays in the Measurement & Control Solutions segment — management characterized this as timing, not share loss, and reiterated municipal demand is resilient (backlog $5.3B). No material tariff impact was flagged.
  2. The subsequent slide to the 52-week low (~$105-113, the "-7.1% since last earnings" Zacks flagged Aug 27) is a different story — driven by (a) an unplanned CFO departure: William Grogan resigned Aug 13/announced Aug 18, effective Aug 31, to become CFO of GE HealthCare (a lateral move to a larger cap, not a for-cause exit); succession is internal (Andrea van der Berg, promoted from SVP Finance of the Water Infrastructure segment, effective Sep 1) which meaningfully reduces the tail risk here — this is not a governance red flag, it's a departure of a well-regarded, poachable finance executive; and (b) a broader industrials/macro rotation — rising borrowing-cost concerns and general risk-off in cyclical/industrial names compressing multiples across the group, not specific to Xylem's order book.

Sell-side read is notably constructive through the decline. Every rating action since the Q2 print (Jul 29 - Aug 24) has been a price-target raise: Jefferies →$150 (Buy), Stifel →$160 (Buy), RBC →$164 (Outperform), Barclays →$159 (Overweight), Baird →$165 (Outperform), Mizuho →$130 (Neutral), UBS →$138 (Neutral). No downgrades. Mean target $153.88 sits ~37% above spot. Analysts appear to be reading the drop as an overreaction to the CFO transition plus macro, not as a reason to cut estimates.

Insider activity is unremarkable-to-mildly-positive — mostly routine RSU vesting/grants and a handful of ordinary 10b5-1-style sales by officers (McShane, Toussaint, Harker) at various prices through 2025-2026, nothing sized or clustered enough to read as a red flag. One modest open-market insider purchase: Director Jerome Peribere bought 1,210 shares (~$141K) at $116.61 on 2026-05-04 — a small golden flag, not decisive on its own.

Verdict on the driver: cyclical/sentiment, not structural. The revenue trim traces to one segment's project timing, the balance sheet and dividend coverage are untouched, the CFO exit has an internal successor already named, and sell-side targets are rising through the decline. This reads as "quality-on-sale" rather than a value trap — with the caveat that the MCS segment bears watching next print to confirm "timing" rather than emerging AMI competitive pressure.

5. Synthesis — Weighted Verdict

Xylem is a mature, moderate-growth, dividend-growing industrial — per the framework, Fundamentals + Valuation carry the most weight here, with Moat and Sentiment as important context rather than the deciding lenses (the reverse weighting from a high-growth SaaS name).

Tensions worth naming explicitly, not burying: - Fundamentals vs. headline growth story: the reported 3yr CAGRs are deal-inflated; organic per-share growth is real but far more modest (~7% revenue/share, ~20% FCF/share, the latter driven mostly by margin expansion that just went negative YoY for the first time since the deal). Don't buy this as a "compounder" story at compounder multiples — the case is "quality industrial, temporarily cheap," not "structural growth machine." - Valuation: Graham/DDM (~$56-82) sit well below both the multiple-based fair value ($107-130) and spot ($112.65). This is a genuine close call, not a clean value case — the bull side requires trusting the adjusted-EPS guide and a modest multiple re-rating; the bear side (Graham/DDM) says the market is still paying up for growth that has structurally slowed. - Moat vs. sentiment: the moat is real in core water infrastructure but genuinely contestable in the newer AMI/digital-metering layer — which is precisely the segment behind this quarter's guidance trim. The sell-off's proximate causes (CFO exit, macro) look separable from that moat question today, but if the MCS softness recurs next print, it stops being "timing" and starts being evidence against the moat thesis in that segment.

Verdict: ACCUMULATE, conviction 6.5/10. A genuinely strong balance sheet (11.7% debt/assets, 0.26x net debt/EBITDA, 62x interest coverage), a 15-year unbroken dividend-growth streak at a well-covered 41-43% payout, an essential-infrastructure end market with structural tailwinds, and a sell-off whose proximate causes (CFO transition, macro industrials rotation, one segment's order timing) look more cyclical than structural — set against a modest ~7% ROIC, a goodwill-heavy balance sheet still digesting its largest-ever acquisition, decelerating organic growth, and value-model outputs (Graham, DDM) that sit meaningfully below spot. This is a name worth building a position in near the current price, not a screaming buy — the entry zone ($100-115) already contains the current price, which is the point of the "quality-on-sale" flag, but conviction stops short of 7+ because the value models disagree with the multiple-based case and the MCS segment needs one more clean print to confirm the "timing not share-loss" read.

Key risks (name them, don't bury them): 1. MCS/AMI segment softness recurs next print — turns "project timing" into "competitive share loss" in the one part of the business genuinely exposed to disruption. 2. New CFO's first quarter (effective Sep 1) surfaces a negative surprise — internal succession lowers this risk but does not eliminate transition risk entirely. 3. Goodwill impairment risk — 47% of total assets is goodwill from a single deal (Evoqua); a sustained end-market downturn would force that conversation. 4. Graham/DDM discipline — if the market re-prices industrials broadly lower (the macro/rate backdrop cited as part of this sell-off), the value-model floor (~$66-82) is a real downside reference, not just an academic one.

Data Gaps / Caveats

  • roic.ai (free tier) only returned 2 years of annual history (2024-2025) rather than the full 5-8yr depth the framework prefers; the multi-year fundamentals table above is built from fin.py's 4-year statement history instead, cross-checked against roic.ai where both overlap.
  • Yahoo's forwardEps field appears to be off-fiscal-year (see pitfall above) — all forward-multiple math here uses Xylem's own guidance, not that field.
  • DDM output is highly sensitive to the assumed growth rate at these discount-rate levels; treat it as a floor check, not a point estimate.